Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 591,300
  • Shares Outstanding, K 91,391
  • Annual Sales, $ 420 K
  • Annual Income, $ -70,790 K
  • 60-Month Beta 1.38
  • Price/Sales 1,332.37
  • Price/Cash Flow N/A
  • Price/Book 5.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.16
  • Number of Estimates 3
  • High Estimate -0.11
  • Low Estimate -0.18
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.17 +6.81%
on 03/15/19
7.38 -10.70%
on 02/26/19
-0.61 (-8.47%)
since 02/25/19
3-Month
5.57 +18.31%
on 12/26/18
7.85 -16.05%
on 01/16/19
+1.08 (+19.60%)
since 12/24/18
52-Week
5.01 +31.54%
on 04/03/18
7.85 -16.05%
on 01/16/19
+1.34 (+25.52%)
since 03/23/18

Most Recent Stories

More News
Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Company") today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts,...

AUP.TO : 8.81 (+1.38%)
AUPH : 6.59 (+1.85%)
Aurinia Pharmaceuticals Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 19, 2019 / Aurinia Pharmaceuticals Inc. (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 19, 2019 at 4:30...

AUPH : 6.59 (+1.85%)
Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease

In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a late clinical-stage biopharmaceutical company with research ongoing in...

AUP.TO : 8.81 (+1.38%)
AUPH : 6.59 (+1.85%)
Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AUPH : 6.59 (+1.85%)
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the "Company") today announced that it will release its fourth quarter and full year 2018 financial results on Tuesday, March 19, 2019,...

AUP.TO : 8.81 (+1.38%)
AUPH : 6.59 (+1.85%)
Aurinia Closes At-The-Market Facility

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the "Company") today announced that, further to its Open Market Sale Agreement with Jefferies LLC previously disclosed on November 30,...

AUP.TO : 8.81 (+1.38%)
AUPH : 6.59 (+1.85%)
Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis

--Claims have the potential to protect voclosporin's method of use and dosing protocol for LN until December 2037

AUP.TO : 8.81 (+1.38%)
AUPH : 6.59 (+1.85%)
Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City

VICTORIA, British Columbia, Feb. 20 -- Aurinia Pharmaceuticals Inc. issued the following news release:

AUP.TO : 8.81 (+1.38%)
AUPH : 6.59 (+1.85%)
Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City

Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a corporate overview at the 8th Annual SVB...

AUP.TO : 8.81 (+1.38%)
AUPH : 6.59 (+1.85%)
Factors of Influence in 2019, Key Indicators and Opportunity within Leidos, Nomad Foods, Huron Consulting Group, Casella Waste, The Medicines, and Aurinia Pharmaceuticals -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Leidos Holdings, Inc. (NYSE:LDOS),...

AUPH : 6.59 (+1.85%)
MDCO : 26.76 (+0.68%)
CWST : 35.34 (+1.26%)
HURN : 47.11 (+1.25%)
NOMD : 20.51 (+1.38%)
LDOS : 62.63 (-0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade AUPH with:

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Key Turning Points

2nd Resistance Point 6.74
1st Resistance Point 6.67
Last Price 6.59
1st Support Level 6.45
2nd Support Level 6.30

See More

52-Week High 7.85
Fibonacci 61.8% 6.77
Last Price 6.59
Fibonacci 50% 6.43
Fibonacci 38.2% 6.09
52-Week Low 5.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar